Ontvang nu dagelijks onze kooptips!

word abonnee
Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

Laatste koers (eur) Verschil Volume
0,707   +0,005   (+0,71%) Dagrange 0,702 - 0,722 4.060.253   Gem. (3M) 3,2M

Pharming November 2022

3.524 Posts
Pagina: «« 1 ... 87 88 89 90 91 ... 177 »» | Laatste | Omlaag ↓
  1. forum rang 6 holmes 15 november 2022 09:17
    Uit:

    Orchard Therapeutics Reports Third Quarter 2022 Financial Results and Reviews Recent Business Highlights

    Research programs:
    Report preclinical POC data for the OTL-104 program in NOD2 Crohn’s disease in early 2023 in advance of IND-enabling studies and an IND submission in 2024.
    Continue to advance the OTL-105 program in hereditary angioedema (HAE), OTL-204 program for GRN-FTD and work in HSC-generated antigen-specific Tregs.

    Collaboration revenue was $0.4 million for the three months ended September 30, 2022, resulting from the collaboration of OTL-105 in HAE with Pharming Group N.V. entered into in July 2021. This revenue represents reimbursements for research costs and preclinical studies incurred by the company and a portion of the $17.5 million upfront consideration received by Orchard under the collaboration, which is being amortized into revenue over the expected duration of the agreement.

    Net loss was $47.6 million for the three months ended September 30, 2022, compared to $36.4 million in the same period in 2021. The company had approximately 128.1 million ordinary shares outstanding as of September 30, 2022.

    ir.orchard-tx.com/news-releases/news-...
3.524 Posts
Pagina: «« 1 ... 87 88 89 90 91 ... 177 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.